eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant.

The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance and all shares of common stock and warrants that comprise the units are being issued as separate securities. The public offering price for a unit is $18.00.

Total gross proceeds from the offering are expected to be approximately $5.33 million before deducting underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on June 9, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriter a 45 day option to purchase up to 44,420 units at the unit offering price, less underwriting discounts and commissions, solely to cover over-allotments, if any.